---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Budget impact model"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Budget impact model. Covers Budget impact model discussion. 1 evidence topic quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics/budget-impact"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Budget impact model

<a id="heading-4.2"></a>

## 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

#### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

#### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

### 4.2.7 Budget impact model discussion

<a id="topic-4.2.7-1"></a>

#### Summary

No budget impact model for ersodetug in tumor hyperinsulinism has been published, and the manufacturer has published no price. The report holds the following inputs for one:

- Eligible population: the manufacturer's U.S. estimates of approximately 3,000 patients per year (Form 10-K) or approximately 4,000 patients per year (Form 10-Q) as the immediately addressable incidence market, approximately 4,500 patients as the total addressable market (2024 release), and about 2,500 malignant insulinoma and about 1,500 NICTH patients as a point-in-time prevalence as of October 2026 (October 2026 presentation). Each figure describes a different measure.
- Treatment setting: the manufacturer believes 60% of patients are managed at National Cancer Institutes and academic medical centers.
- Drug use: the studied regimen is 9 mg/kg weekly for 8 weeks, followed by extension dosing every 2 to 4 weeks. The manufacturer assumes about 80 kg average adult weight, 9 vials per infusion, and 117 vials per year per patient with infusion every four weeks.
- Payer mix: Medicare 48.6%, commercial 43.9%, Medicaid 5.5%, and other 2.0% of patients in the company's claims data.
- Price: no wholesale acquisition cost or average sales price exists for the investigational product. The manufacturer's payer research describes expected ultra-rare disease pricing and weight-based pricing with reimbursement through a J-code.

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm); [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
